ImaRx Therapeutics and contrast media firm Guerbet of Roissy, France, have signed an agreement to jointly develop an MR contrast agent aimed at visualizing cancers at the molecular level.
Formulations will be developed using the Tucson, AZ-based company's nanodroplet technology in combination with Guerbet's targeting ligands and MR contrast agents. Terms of the deal were not disclosed.
By AuntMinnie.com staff writers
December 10, 2004
Related Reading
ImaRx completes private placement, names chairman, April 2, 2004
ImaRx inks licensing deal, November 19, 2003
Clinical trials begin for ImaRx, September 18, 2003
Ultrasound bubbles over into therapy, February 12, 2001
Copyright © 2004 AuntMinnie.com
